NIA

Hevolution Foundation Announces Pilot Grants Program for Top Healthspan-Related Research in the United States

Retrieved on: 
Monday, October 31, 2022
Health, Other Science, General Health, Research, Science, Biotechnology, Entrepreneurship, Government, Life, Research, Biology, Foundation, National Institute, Ageing, NIA, Doctor of Philosophy, Drug development, National Institute on Aging, NIH, Review, Goal, Therapy, Science, Pharmaceutical industry

Hevolution Foundation , a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science, is launching a new grants program in the United States, Hevolution Foundation - Advancing Geroscience Efforts (HF-AGE).

Key Points: 
  • Hevolution Foundation , a non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science, is launching a new grants program in the United States, Hevolution Foundation - Advancing Geroscience Efforts (HF-AGE).
  • Applications for HF-AGE will be submitted to Hevolution Foundation as described in the Grant Guidelines .
  • With HF-AGE, we will leverage Hevolution Foundations resources and expertise to take such promising research to the next level.
  • HF-AGE is an independent initiative of Hevolution Foundation, which is not affiliated with the NIH, the NIA, or the US government.

Nonprofits Insurance Alliance Receives AM Best “A (Excellent)” Rating for Financial Strength

Retrieved on: 
Thursday, October 20, 2022
Professional Services, Philanthropy, Legal, Insurance, Other Philanthropy, Fund Raising, Foundation, NIAC, Risk management, ANI, ICR, AM Best, Risk retention group, Nonprofits Insurance Alliance, Organization, NIA, IX, Alliance, Industry, AMS, Nonprofit organization, National Alliance, RRG, Insurance, Insurance

Nonprofits Insurance Alliance (NIA) received strong reviews of its financial strength and overall credit rating from AM Best, the insurance industrys leading credit rating agency.

Key Points: 
  • Nonprofits Insurance Alliance (NIA) received strong reviews of its financial strength and overall credit rating from AM Best, the insurance industrys leading credit rating agency.
  • NIAs A (Excellent) rating is cited in the agencys IX financial size rating category.
  • NIAs three insurance entities collectively received a Financial Strength Rating of A (Excellent) and Issuer Credit Rating (ICR) of a+ a reflection of NIAs balance sheet strength, which AM Best categorizes as Strongest.
  • The NIA brand is comprised of Alliance Member Services (AMS) and three AM Best A (Excellent) rated insurers: Nonprofits Insurance Alliance of California (NIAC); Alliance of Nonprofits for Insurance, RRG (ANI); and National Alliance of Nonprofits for Insurance (NANI).

NIA’s Photo Contest Offers Nonprofits Chance to Win Cash

Retrieved on: 
Thursday, October 20, 2022
Foundation, Professional Services, Insurance, Philanthropy, NIAC, ANI, Review, Nonprofits Insurance Alliance, Organization, NIA, Industry, AMS, Nonprofit organization, National Alliance, RRG, Management, Wool, Alliance, Insurance

Nonprofits Insurance Alliance (NIA) wants to see how community nonprofits are Making a Better World, the theme of this years NIA Photo Contest.

Key Points: 
  • Nonprofits Insurance Alliance (NIA) wants to see how community nonprofits are Making a Better World, the theme of this years NIA Photo Contest.
  • The contest has expanded from NIA member nonprofits to include any U.S. 501(c)(3) nonprofit that subscribes to BlueAvocado.org , a free online magazine for nonprofits.
  • The 2022 NIA Photo Contest will name 12 winners:
    The top prize of $1,000 will go to the nonprofit organization whose image best communicates the theme.
  • Nonprofits Insurance Alliance (NIA) is the nations leading property and casualty insurer exclusively serving nonprofit organizations.

Rendever Deploys Virtual Reality Program at The Oaks at Algonquin Senior Living to Increase Enrichment for Residents

Retrieved on: 
Monday, October 17, 2022
Benchmark, AARP, Retirement, Assisted living, Social isolation, Life, Virtual reality, VP, Loneliness, Organization, LLC, Hospital, Depression, Research, NIH, Program, NIA, SRG, Spectrum, Partnership, Health, Cheese, Broadway, Cleveland Clinic, Revera, GLOBE, The Oaks, Ageing, Travel, UCHealth, Verizon Communications, Tourism, Algonquin

ALGONQUIN, Ill., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Rendever, a company pioneering the future of aging, partners with The Oaks at Algonquin Senior Living to boost health and wellness, increase engagement, and create positive shared experiences among senior residents.

Key Points: 
  • ALGONQUIN, Ill., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Rendever, a company pioneering the future of aging, partners with The Oaks at Algonquin Senior Living to boost health and wellness, increase engagement, and create positive shared experiences among senior residents.
  • The senior living community launched the partnership with an interactive, month-long event called World Explorers of Algonquin.
  • During this program, 45 residents are signed on to travel to new destinations around the world three times a day through Rendevers virtual reality sessions.
  • To create a truly immersive experience for residents, The Oaks at Algonquin team paired each session with an educational and culturally competent activity.

Vuzix Blade Smart Glasses Support Xpertinc's Closed Captioning C-Sound Solution for the Deaf and Hearing Impaired

Retrieved on: 
Monday, October 17, 2022
Blade, News, U.S. Securities and Exchange Commission, API, Private Securities Litigation Reform Act, Augmented reality, NRC, AR, Facial expression, NASDAQ, KEAD, Smartglasses, Twitter, Rancho Los Amigos National Rehabilitation Center, NIA, Facebook, Technology, Human, Company, Learning, CES, MD, AI, IP, Intention, Wireless, Artificial intelligence, Government, Consumer Electronics Show, Mouth, Solution, Risk, Television, Vuzix

Xpertinc recently placed an initial volume order for Vuzix Blade smart glasses and has commenced customer shipments of this solution.

Key Points: 
  • Xpertinc recently placed an initial volume order for Vuzix Blade smart glasses and has commenced customer shipments of this solution.
  • In addition, an application applied with UI/UX and open API for user convenience was developed and mounted.
  • "Xpertinc's C-Sound solution is yet another example of how Vuzix smart glasses are directly helping improve people's lives," said Paul Travers, President and Chief Executive Officer at Vuzix.
  • Vuzix is a leading supplier of Smart Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets.

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

Retrieved on: 
Wednesday, October 12, 2022
Lewy body, Therapy, Diagnosis, Degenerative disease, Delusion, Vance DeGeneres, Lewy, Hallucination, Private Securities Litigation Reform Act, Retina, Patient, Sleep, MPH, Mental health, NIA, Dementia, Nasdaq, Awareness, Risk, LBD, University, Neurology, Lewy Body Dementia Association, Neuron, U.S. Securities and Exchange Commission, National, Â, Securities & Exchange Commission of Pakistan, SHIMMER, Safety, Cognition, DLB, GLOBE, Neurodegeneration, Brain, Intellectual property, Practitioner, Pathology, Central nervous system, Biomarker, Pharmaceutical industry, Medicine, MD

The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.

Key Points: 
  • The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.
  • This month is Lewy Body Dementia Awareness month with approximately over 1.4 million people in the United States suffering from the neurodegenerative disease, making it the second most common form of dementia.
  • Often misdiagnosed it also masks itself as Parkinsons disease and is the largest dementia most have never heard of.
  • This October, during Lewy Body Dementia Awareness Month, lets recommit to educating ourselves about LBD.

How Women Lead #GetonBoard Week Honorees Are Helping Catapult Fearless Women Leaders into Board Seats

Retrieved on: 
Tuesday, October 11, 2022
Professional Services, Philanthropy, Training, Consumer, Fund Raising, Education, Foundation, Labor, Other Professional Services, Women, Human Resources, Other Philanthropy, Public Policy, Government, Movement, Female, Life, Woman, Organization, NASDAQ, Progress, Fearless, Lead, Man, Missing, NIA, Investment, Priority, Technology, First Republic Bank, Ruby Stutts Lyells, Goal, University of Global Health Equity, Â, Salesforce, CEO, Workplace, PDT, CalPERS, BlackRock, Entrepreneurship, Leadership, Medicine, Management, Renewable energy

The awards recognize people and companies for their impactful work creating more equity for women in the workplace.

Key Points: 
  • The awards recognize people and companies for their impactful work creating more equity for women in the workplace.
  • The award ceremony will take place during How Women Leads #GetOnBoard weeklong summit of advocacy and action to catapult fearless women leaders into board seats, taking place October 17-21, 2022.
  • Marys zest for helping others reach their goals is truly inspiring, said Julie Castro Abrams, CEO of How Women Lead.
  • Through her work, Mary has empowered hundreds of women to advance their careers and gain positions of power in their industries.

CND Life Sciences Awarded Third NIH SBIR Grant to Study the Syn-One Test® in Patients Diagnosed with REM Sleep Behavior Disorder (RBD)

Retrieved on: 
Thursday, October 6, 2022
Lewy body, National Institute, Movement, Risk, PD, REM, Diagnosis, Neurodegeneration, Patient, MSA, Behavioural sciences, Sleep, Government budget balance, National Institute of Neurological Disorders and Stroke, Parkinson's disease, Research, NIH, Lists of diseases, CND, National Institute on Aging, NIA, Dementia, Synucleinopathy, SBIR, Psychiatry, MD, Pure autonomic failure, NAPS, AI, RBD, National, Neurology, PAF, Multiple system atrophy, DLB, Alpha-synuclein, Gold, Stanford University, Dysautonomia, Radical behaviorism, Stroke, Rapid eye movement sleep behavior disorder, Movement disorders, Pathology, Pharmaceutical industry, Medical imaging

PHOENIX, Oct. 6, 2022 /PRNewswire/ -- CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). This is the third NIH SBIR Phase II award for the company to study and advance the clinical application of the Syn-One Test, the only commercially available test that uses skin biopsies to help clinicians diagnose a synucleinopathy, a family of neurodegenerative diseases that includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), pure autonomic failure (PAF) and REM sleep behavior disorder (RBD).

Key Points: 
  • Patients diagnosed with RBD experience vivid, often disruptive dreams associated with simple or complex motor behavior during the REM phase of sleep.
  • The success of future treatments for these disorders will be tied to how precisely and early we can understand the patient's pathology," explained Levine.
  • Founded in 2017, CND Life Sciences is dedicated to supporting the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions.
  • The company has research collaborations with multiple biopharmaceutical companies and has been awarded three prestigious NIH SBIR grants to advance the validation and clinical utility of its Syn-One Test.

Ro Announces Agreement with the NIH National Institute on Aging (NIA) to Diversify Clinical Trial Registration Using its Telehealth Platform

Retrieved on: 
Thursday, October 6, 2022
DREAM, National Institute, Insurance, Disease, Risk, Transport, CTNS, Population, Hope, Translational Genomics Research Institute, Diagnosis, Drug, Patient, Drug development, Medication, Research, NIH, IRB, National Institute on Aging, Multimedia, NIA, Dementia, Clinical, Translational neuroscience, Technology, NEW, Goal, National, CEO, AD, Telehealth, Death, COVID-19, EHR, Medical imaging, Pharmaceutical industry, MD, Alzheimer's disease

NEW YORK, Oct. 6, 2022 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today, announced an agreement with the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to create the "Registry for Equal Access to Clinical Trials in Alzheimer's Disease (AD)" (REACT-AD). As part of the agreement, Ro will use its telehealth platform to screen and recruit patients who may be at an elevated risk for AD or a related dementia to join a registry of potential participants in NIA-conducted and funded clinical trials. The agreement reflects a shared interest in advancing patient-centric, technology-driven clinical research strategies.

Key Points: 
  • The agreement reflects a shared interest in advancing patient-centric, technology-driven clinical research strategies.
  • This initiative demonstrates how Ro can help our patients achieve their health goals, whether through care on our platform or by connecting them to world-class clinical trials."
  • The ongoing COVID-19 pandemic has further undermined recruitment of patients into clinical trials through traditional methods.
  • The goal of the REACT-AD initiative is to use Ro's telemedicine platform that serves a large and decentralized population to diversify the participants recruited for clinical trials.

Praetego Inc Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer's Disease

Retrieved on: 
Tuesday, October 4, 2022
Inflammation, School, Central nervous system disease, Neurodegeneration, NIA, Medical school, Oxidative stress, Diabetes, IND, National Institute, Alzheimer's disease, NIH, Advanced glycation end-product, Protein, Central nervous system, Ageing, Pathology, Kidney, AGE, San Diego, National Institute of Diabetes and Digestive and Kidney Diseases, AD, Patient, Principal, STTR, DPN, University, Apoptosis, Rapunzel's Tangled Adventure (season 2), NIDDK, Therapy, Digestive, Neuroprotection, National Institute on Aging, Pharmaceutical industry

The Phase 2 award advances Praetego's lead candidate, PTG-630, against Alzheimer's disease (AD).

Key Points: 
  • The Phase 2 award advances Praetego's lead candidate, PTG-630, against Alzheimer's disease (AD).
  • The award allows Praetego to accelerate development of PTG-630 towards preventing the progression of Alzheimer's Disease (AD).
  • Praetego's grant follows promising findings obtained during a supplemental award from the NIA targeted at novel AD therapeutics.
  • This ongoing support from the NIH has enabled Praetego to progress its novel scientific approach to disorders of aging and neurodegeneration, and specifically AD."